
    unable to enroll
  
['multiple sclerosis']
['95% pure ecgc capsules 200mg', 'placebo comparator:']

        Inclusion Criteria:

          -  Diagnosis of MS by McDonald criteria

          -  Relapsing-remitting MS or secondary progressive MS

          -  Stable therapy with Copaxone, Rebif, Betaseron or Avonex 30 mcg for at least six
             months

          -  EDSS Score less than or equal to 7.0

          -  Ages 18-60.

          -  Participants must have normal organ and marrow function as defined below:

               -  Leukocytes ≥3,000/µL

               -  Absolute neutrophil count ≥1,500/µL

               -  Platelets ≥100,000/µL

               -  Total bilirubin ≤local upper limit of normal

               -  AST (SGOT) ≤local upper limit of normal

               -  ALT (SGPT) ≤local upper limit of normal

               -  Creatinine ≤local upper limit of normal

        Exclusion Criteria:

          -  MS relapse within the 30 days prior to enrollment

          -  A primary progressive form of MS.

          -  Previous treatment prior to study entry as follows: complete radiation ablation of the
             bone marrow or anti-CD4 antibody treatment (Campath) at any time; mitoxantrone,
             cyclophosphamide, Natalizumab or other immunomodulatory or immunosuppressant therapies
             except the DMT's included in the inclusion criteria and methylprednisone for relapses
             within prior nine months.

          -  History of renal or liver disease.

          -  Consumption of green tea or supplements containing green tea or tea extract within 30
             days prior to enrollment.

          -  Participants may not participate in any other clinical trial involving investigational
             agents during the study, or within six months prior to enrolling in the study.

          -  History of allergic reactions attributed to compounds of similar chemical or biologic
             composition to Polyphenon E, tea, or any of the inactive ingredients present in the
             active or placebo capsules, including gelatin.

          -  History of allergic reactions to gadolinium or any other condition contraindicated for
             MRI.

          -  Uncontrolled, clinically-relevant active illness (aside from MS) including, but not
             limited to, ongoing or active infection, symptomatic congestive heart failure,
             unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations
             that would limit compliance with study requirements.

          -  Any condition which would make the subject, in the opinion of the investigator,
             unsuitable for the study

          -  Inability to complete the baseline MRI scan

          -  Pregnant women

          -  Any underlying predisposition to gastrointestinal bleeding (peptic ulcer disease,
             gastritis, diverticulitis, colitis, hemorrhoids)
      